Key statistics dashboard for Vyome Holdings, Inc. (HIND). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
Stock Data
| Price | $1.96 |
| Market Cap | $14M |
| Enterprise Value | $5.9M |
| Beta | 1.42 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.07 |
| Price / Book | 2.26 |
| P/S | 105.50 |
| EV/EBITDA | -0.51 |
| EV/Sales | 45.37 |
| EV/FCF | 11.22 |
| P/FCF | 26.10 |
| Earnings Yield | -82.20% |
| FCF Yield | 3.81% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 46.50% |
| EBIT Margin | -8894.63% |
| EBITDA Margin | -8886.37% |
| Operating Margin | -3250.25% |
| Net Margin | -8716.77% |
| Return on Equity | -254.62% |
| Return on Assets | -123.23% |
| Return on Invested Capital | -57.53% |
| Return on Capital Employed | -57.67% |
Financial Health
| Current Ratio | 4.37 |
| Quick Ratio | 4.37 |
| Cash Ratio | 4.23 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.19% |
| Net Debt / EBITDA | 0.68 |
| Interest Coverage | -101.07 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -18.08 |
Per-Share Data
| Revenue per share | 0.02 |
| Book Value per share | 1.04 |
| Cash per share | 1.12 |
| FCF per share | 0.07 |
| Tangible Book Value per share | 1.00 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 1 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 3 |
| Avg rating (1-5) | 0.33 |
Related companies: ARMP · CCCC · CDXS · CGEN · IMDX · IPHA · NVCT
Explore sector: Healthcare · Biotechnology
More sections of HIND: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks